pharma · Carcinoma, Non-small-cell Lung · Type 2 Diabetes Mellitus · LGND
LIGAND PHARMACEUTICALS
LIGAND PHARMACEUTICALS INC
Ligand Pharmaceuticals is a pharma organization headquartered in Jupiter, USA. It trades on NYSE under ticker LGND. Primary therapeutic focus areas include Carcinoma, Non-small-cell Lung, Type 2 Diabetes Mellitus, Sarcom
555 Heritage Dr, Suite 200, Jupiter, Florida 33458, US HQ
1987 Founded
130 Employees
Public company Type
LGND · NYSE Ticker
Company details
- Status
- Public
- HQ
- 555 Heritage Dr, Suite 200, Jupiter, Florida 33458, US
- Founded
- 1987
- Employees
- 130
- Programs
- 34
- Drugs
- 25
- Patents
- 133
Bexarotene (Targretin®)
Phase 1 · small molecule · Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus)
Bexarotene (Targretin®) for Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus) is a Phase 1 program (small_molecule) at LIGAND PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Internal code D0228
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- LIGAND PHARMACEUTICALS INC
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus)
- Status
- completed
- Trials
- 1